Perspective Therapeutics Inc. (CATX)
NYSE · Healthcare
Perspective Therapeutics Inc. EBITDA 2020–2025
Perspective Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Perspective Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -25.0 M, a 44.12% increase year-over-year.
- Perspective Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -108.4 M.
- Perspective Therapeutics Inc. annual ebitda for 2025 was -100.8 M, a 86.72% increase from 2024.
- Perspective Therapeutics Inc. annual ebitda for 2024 was -54.0 M, a 38.15% increase from 2023.
- Perspective Therapeutics Inc. annual ebitda for 2023 was -39.1 M, a 447.05% increase from 2022.
- Perspective Therapeutics Inc. annual ebitda for 2022 was -7.1 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Perspective Therapeutics Inc. EBITDA — FAQ
Perspective Therapeutics Inc. (CATX) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CATX's ebitda history?
The chart and table above show Perspective Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.